INmune Bio Inc. (INMB)
| Market Cap | 55.51M +7.1% |
| Revenue (ttm) | n/a +257.1% |
| Net Income | -18.42M |
| EPS | -0.69 |
| Shares Out | 27.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 191,597 |
| Open | 2.020 |
| Previous Close | 2.030 |
| Day's Range | 1.940 - 2.045 |
| 52-Week Range | 1.090 - 2.600 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+250.0%) |
| Est. Earnings | Oct 29, 2026 |
About INMB
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatmen... [Read more]
Financial Performance
In 2025, INmune Bio's revenue was $50,000, an increase of 257.14% compared to the previous year's $14,000. Losses were -$45.93 million, 9.15% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for INMB stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 250.00% from the latest price.
News
INmune Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Two late-stage platforms advance non-immunosuppressive inflammation therapies, with CORDStrom (Ebstrocel) leading regulatory filings for RDEB and showing strong clinical and patient-reported outcomes. Manufacturing and regulatory milestones are on track, with broad patient demand and future platform potential.
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE ...
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept.
INmune Bio submits two regulatory packages to EMA for Ebstrocel
INmune Bio (INMB) announced that it has submitted two regulatory packages to the European Medicines Agency, or EMA, for Ebstrocel: an application for orphan drug designation and a scientific advice…
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained th...
INmune Bio Earnings Call Transcript: Q2 2026
Key regulatory and manufacturing milestones for Ebstrocel and XPro were achieved, with Ebstrocel approaching global filings and XPro advancing in Alzheimer's. Financials improved with a lower net loss and strong cash position, supporting operations into Q2 2027.
INmune Bio Quarterly report: Q2 2026
INmune Bio has published its Q2 2026 quarterly earnings report on August 6, 2026.
INmune Bio Earnings release: Q2 2026
INmune Bio released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
INmune Bio receives $4.6M in rebates from Australia, UK
INmune Bio (INMB) announced that on July 30, it received a research and development cash rebate from Australia of approximately $4.2M. This rebate is in addition to approximately $0.4M of…
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology c...
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on J...
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities
INmune Bio processes first umbilical cord tissue at CGT Catapult
INmune Bio (INMB) announced the company has successfully processed its first commercial-ready umbilical cord tissue at the Cell and Gene Therapy Catapult Manufacturing Innovation Centre in Stevenage, ...
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Dis...
INmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
The study points to soluble TNF as a key biological link between head injury and Alzheimer's disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloi...
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition.
INmune Bio advances CORDStrom platform patent application in the U.S.
INmune Bio (INMB) announced that it has submitted its CORDStrom platform patent application into the U.S. national phase before the United States Patent and Trademark Office, or USPTO. Published first...
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045
INmune Bio receives MHRA approval for Ebstrocel pediatric investigation plan
INmune Bio (INMB) announced that the UK Medicines & Healthcare products Regulatory Agency, or MHRA, has approved the pediatric investigation plan, or PIP, for Ebstrocel for the treatment of Recessive…
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the United Kingdom
INmune Bio announces MHRA alignment in pre-MAA CORDStrom meeting
INmune Bio (INMB) announced that it has received official, accepted meeting minutes from its recent face-to-face pre-Marketing Authorization Application, or pre-MAA, Scientific Advice meeting with the...
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical evidence packages MHRA pediatric feedback recognizes Mission...
INmune Bio Transcript: AGM 2026
The meeting addressed board elections, auditor ratification, and an amended stock incentive plan, all of which were approved by stockholders. A quorum was present, and final voting results will be filed with the SEC. Stockholders participated in a Q&A session.
INmune Bio reports positive MRI data in Phase 2 Alzheimer’s trial
INmune Bio (INMB) announced positive results from exploratory MRI imaging analyses of its MINDFuL Phase 2 trial of XPro in patients with early Alzheimer’s disease. “A statistically significant treatme...
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.